Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Rep. Upton To Hold FDA, Device Industry Y2K Compliance Hearing

This article was originally published in The Gray Sheet

Executive Summary

House Commerce/Oversight and Investigations Subcommittee Chairman Fred Upton (R-Mich.) is planning a year 2000 compliance hearing with testimony from FDA and medical device manufacturers.

You may also be interested in...

GAO Optimistic About FDA Y2K Readiness Measures For High-Risk Devices

The General Accounting Office has a higher level of confidence in year 2000 readiness of high-risk medical devices than it did roughly five months ago, GAO Civil Agencies Information Systems Accounting and Information Management Division Director Joel Willemssen said.

Resolving Botanicals Deadlock 'Not A Priority' For European Commission

Tensions between industry and the European Commission on the issue of  health claims for botanical food supplements were aired on the second day of the BAH's High Level Conference on the Future of Medicines, with the EC saying the EU Green Deal is now higher up on its list of priorities for the foreseeable future. 




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts